Research ArticleBasic Science Investigations
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Mohamed Altai, Anna Perols, Maria Tsourma, Bogdan Mitran, Hadis Honarvar, Marc Robillard, Raffaella Rossin, Wolter ten Hoeve, Mark Lubberink, Anna Orlova, Amelie Eriksson Karlström and Vladimir Tolmachev
Journal of Nuclear Medicine March 2016, 57 (3) 431-436; DOI: https://doi.org/10.2967/jnumed.115.162248
Mohamed Altai
1Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Anna Perols
2Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden
Maria Tsourma
1Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Bogdan Mitran
3Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, Uppsala, Sweden
Hadis Honarvar
1Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Marc Robillard
4Tagworks Pharmaceuticals, Eindhoven, The Netherlands
Raffaella Rossin
4Tagworks Pharmaceuticals, Eindhoven, The Netherlands
Wolter ten Hoeve
5Syncom, Groningen, The Netherlands; and
Mark Lubberink
6Institute for Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden
Anna Orlova
3Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, Uppsala, Sweden
Amelie Eriksson Karlström
2Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden
Vladimir Tolmachev
1Institute for Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 3
March 1, 2016
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Mohamed Altai, Anna Perols, Maria Tsourma, Bogdan Mitran, Hadis Honarvar, Marc Robillard, Raffaella Rossin, Wolter ten Hoeve, Mark Lubberink, Anna Orlova, Amelie Eriksson Karlström, Vladimir Tolmachev
Journal of Nuclear Medicine Mar 2016, 57 (3) 431-436; DOI: 10.2967/jnumed.115.162248
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Mohamed Altai, Anna Perols, Maria Tsourma, Bogdan Mitran, Hadis Honarvar, Marc Robillard, Raffaella Rossin, Wolter ten Hoeve, Mark Lubberink, Anna Orlova, Amelie Eriksson Karlström, Vladimir Tolmachev
Journal of Nuclear Medicine Mar 2016, 57 (3) 431-436; DOI: 10.2967/jnumed.115.162248
Jump to section
Related Articles
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- Pretargeted Imaging and Therapy
- Chemical Tools for Studying Lipid-Binding Class A G Protein-Coupled Receptors